- Home
- EYPT vs TLRY Comparison
EYPT vs TLRY Comparison
Compare EYPT & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | TLRY |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EYPT | TLRY |
|---|---|---|
| Price | $18.26 | $10.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $29.60 | ★ $150.00 |
| AVG Volume (30 Days) | 1.3M | ★ 20.0M |
| Earning Date | 11-05-2025 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $42,339,000.00 | ★ $830,766,000.00 |
| Revenue This Year | N/A | $7.28 |
| Revenue Next Year | N/A | $4.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.31 |
| 52 Week Low | $3.91 | $3.51 |
| 52 Week High | $19.11 | $23.20 |
Technical Indicators
Market Signals| Indicator | EYPT | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 61.70 |
| Support Level | $16.52 | $9.82 |
| Resistance Level | $19.00 | $15.70 |
| Average True Range (ATR) | 1.04 | 1.48 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 74.24 | 34.61 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.